*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Medtide Inc.**

**泰德醫藥(浙江)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3880)**

# (1) POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON NOVEMBER 18, 2026; AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

References are made to (i) the circular (the "**Circular**") and (ii) the notice (the "**Notice**") both dated October 29, 2026 issued by Medtide Inc. (the "**Company**") in relation to the 2026 first extraordinary general meeting of the Company (the "**EGM**"). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

## THE 2026 FIRST EXTRAORDINARY GENERAL MEETING

The Board is pleased to announce that the EGM was held at 9:00 a.m. on Wednesday, November 18, 2026 at No. 69, 12 Street, Qiantang District, Hangzhou, Zhejiang, the PRC.

As at the time of the EGM, the Company had a total of 141,800,000 H Shares in issue. None of the H Shares was held as treasury Shares (including any treasury Shares held or deposited with the Central Clearing and Settlement System operated by Hong Kong Securities Clearing Company Limited), and no voting rights attached to the treasury Shares may be exercised at the EGM. The total number of Shares entitling the holders to attend and vote for or against all the resolutions in the Notice proposed at the EGM was 141,800,000. There were no repurchased Shares which are pending cancellation and accordingly should be excluded from the total number of issued Shares for the purposes of the EGM. There were no Shares entitling the holder to attend and abstain from voting in favour of any resolutions proposed for consideration and approval by the Shareholders at the EGM as set out in Rule 13.40 of the Listing Rules. No Shareholders were required to abstain from voting at the EGM under the Listing Rules and none of the Shareholders has stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed for consideration and approval by the Shareholders at the EGM.

The EGM was legally and validly convened in compliance with the requirements of the Company Law of the PRC, the relevant laws and regulations of the PRC, the Listing Rules and the articles of association of the Company. All Directors, namely, Dr. Xu Qi, Dr. Li Xiang, Ms. Li Xiangli, Ms. Cheng Tao, Mr. Wu Yihui, Dr. Yu Cheung Hoi, Dr. Zhu Xun and Mr. Xia Xinsheng, attended the EGM in person or by electronic means.

The Company's H Share Registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the EGM.

All the resolutions as set out in the Notice were put to vote by way of poll by the Shareholders (including their proxies and authorized representatives) at the EGM.

## POLL RESULTS OF THE EGM

The poll results of the proposed resolutions (the "**Resolutions**") at the EGM were as follows:

| **SPECIAL RESOLUTIONS**[(1)] | | **Number of votes (%)** | | |
|---|---|---|---|---|
| | | **For** | **Against** | **Abstain** |
| 1. | To consider and, if thought fit, pass the following resolution as a special resolution:<br><br>"**THAT:**<br><br>the adoption of the 2026 Medtide RSU Scheme proposed by the Board, a copy of which is produced to this meeting marked "A" and signed by the Chairwoman of the meeting for the purpose of identification, with the Scheme Mandate Limit (as defined in the 2026 Medtide RSU Scheme) of 10% of the total number of Shares in issue (excluding any treasury shares, if any) as at the date of the Shareholders' approval of the 2026 Medtide RSU Scheme, be and is hereby approved and adopted, and the Board be and is hereby authorised to grant the awards pursuant to the 2026 Medtide RSU Scheme ("**Awards**"), and to do all such acts and execute all such documents as the Board may consider necessary or expedient in order to give full effect to the 2026 Medtide RSU Scheme." | 115,207,375<br>(99.956966%) | 49,600<br>(0.043034%) | 0<br>(0.000000%) |

| SPECIAL RESOLUTIONS[1] | | Number of votes (%) | | |
|---|---|---|---|---|
| | | For | Against | Abstain |
| 2. | To consider and, if thought fit, pass the following resolution as a special resolution:<br><br>"**THAT:**<br><br>conditional upon the passing of special resolution 1, the Service Provider Sublimit (as defined in the 2026 Medtide RSU Scheme) of 1% of total number of Shares in issue (excluding treasury shares, if any) as at the date of the Shareholders' approval of the 2026 Medtide RSU Scheme be and is hereby approved and adopted."<br><br>Special resolution 1 is not conditional upon the passing of special resolution 2, but special resolution 2 is conditional upon the passing of special resolution 1. In the event that special resolution 1 is passed but special resolution 2 is not passed, the Company will adopt the 2026 Medtide RSU Scheme but the Board shall alter the 2026 Medtide RSU Scheme to remove references to the grant of Awards to Service Providers. In the event that special resolution 2 is passed but special resolution 1 is not passed, the 2026 Medtide RSU Scheme will not be adopted. | 115,207,375<br>(99.956966%) | 49,600<br>(0.043034%) | 0<br>(0.000000%) |
| 3. | To consider and approve the proposed amendments to the Articles of Association. | 115,256,975<br>(100.000000%) | 0<br>(0.000000%) | 0<br>(0.000000%) |
| 4. | To consider and approve the proposed amendments to the Procedure Rules for the General Meeting. | 115,256,975<br>(100.000000%) | 0<br>(0.000000%) | 0<br>(0.000000%) |
| 5. | To consider and approve the proposed amendments to the Procedure Rules for the Board of Directors. | 115,256,975<br>(100.000000%) | 0<br>(0.000000%) | 0<br>(0.000000%) |

| ORDINARY RESOLUTIONS | | For | Against | Abstain |
|---|---|---|---|---|
| 6. | To consider and approve the proposed amendments to the Working System for Independent Non-Executive Directors. | 114,103,575 (98.999280%) | 1,153,400 (1.000720%) | 0 (0.000000%) |
| 7. | To consider and approve the proposed amendments to the Management System for External Guarantees. | 114,103,575 (98.999280%) | 1,153,400 (1.000720%) | 0 (0.000000%) |

*Note:*

(1) Please refer to the Circular for the full text of the Resolutions. Ordinary resolutions shall be passed by votes representing more than one-half of the voting rights held by the Shareholders (including proxies thereof) attending the EGM. Special resolutions shall be passed by votes representing at least two-thirds of the voting rights held by the Shareholders (including proxies thereof) attending the EGM.

As at least two-thirds of the votes were cast in favour of special resolutions no. 1 to 5, and more than one-half of the votes were cast in favour of ordinary resolutions no. 6 and 7, all resolutions proposed at the EGM were duly passed by way of poll by the Shareholders.

## AMENDMENTS TO THE ARTICLES OF ASSOCIATION

A special resolution was passed by the Shareholders at the EGM to approve the amendments to the Articles of Association. Accordingly, upon the conclusion of the EGM, the amended Articles of Association shall become effective. The full text of the amended Articles of Association will be published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.medtideinc.com).

By order of the Board
**Medtide Inc.**
**泰德醫藥(浙江)股份有限公司**
**Dr. Xu Qi**
*Chairwoman and Chief Executive Officer*

Hong Kong, November 18, 2026

*As at the date of this announcement, the executive Directors of the Company are Dr. Xu Qi (徐琪), Dr. Li Xiang (李湘), Ms. Li Xiangli (李湘莉) and Ms. Cheng Tao; the non-executive Director of the Company is Mr. Wu Yihui (吳一暉); and the independent non-executive Directors of the Company are Dr. Yu Cheung Hoi (于常海), Dr. Zhu Xun (朱迅) and Mr. Xia Xinsheng (夏心晟).*